Medicovestor raises seed round from Dandelion Ventures for antibody drug R&D

What's the deal? MedicovestorDealroom has a profile for this one. Try Dealroom →, a Chinese antibody drug development services firm, has raised several million renminbi in a seed round backed by Dandelion Ventures. The company develops next-generation antibody drugs and antibody-drug conjugate (ADC) technology.

What's the endgame? Medicovestor draws on an international network of innovative drug development resources. It aims to build precise treatment options with clinical value and commercial potential.

The signal: Early-stage capital continues to flow toward China's antibody and ADC developers, a segment drawing growing interest as drugmakers chase more targeted cancer therapies.

Image credit: National Institutes of Health (NIH)